WebOn July 13, 2024, the Food and Drug Administration approved enzalutamide (XTANDI, Astellas Pharma US, Inc.), for patients with castration-resistant prostate cancer (CRPC). This approval broadens... WebResults: Serial plasma samples and radiographic scans on ARSI treatment were prospectively collected from 73 CRPC with bone mets. Median age was 74 years [interquartile range (IQR) 69-79]. ... Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration …
mCRPC: PREVAIL Trial HCP Site XTANDI® (enzalutamide)
WebWe conducted an IRB-approved retrospective study involving consecutive patients treated with first-line docetaxel chemotherapy for metastatic CRPC at our institution between 2004 and 2014. Only patients who received every-3-weekly docetaxel (at a planned dose of 75mg/m2) were included; those receiving weekly docetaxel were not studied. Webprostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC). Efficacy in mCRPC: PREVAIL Trial TERRAIN Trial AFFIRM Trial Start XTANDI for … railroad boom after civil war
The Influence of Prednisone on the Efficacy of Docetaxel in Men …
WebApr 14, 2024 · Introduction. Castration-resistant prostate cancer (CRPC), particularly metastatic castration-resistant prostate cancer (mCRPC) is one of the most common cancers in males and affects millions of men worldwide with high morbidity and mortality (Siegel et al., 2024).Treatments for mCRPC are various including chemotherapy, … WebMay 12, 2024 · Metastatic CRPC: Clinical Pearls and Practical Advice. Transcript: Scott Tagawa, MD, MS, FACP: For our patients with advanced prostate cancer—all stages and lines of therapy, including ... WebPurpose: As a direct result of the significant increase in multiple FDA- approved therapeutic agents for use in patients with metastatic castration- resistant prostate cancer (CRPC), … railroad bonds